Revolution Medicines Inc.
Revolution Medicines Reports Positive Clinical Data for Daraxonrasib in Pancreatic Cancer Treatment
Summary
Revolution Medicines, Inc. reported updated clinical data for daraxonrasib, its RAS(ON) multi-selective inhibitor, showing positive safety, tolerability, and activity profiles in patients with RAS-mutant pancreatic ductal adenocarcinoma (PDAC). In the Phase 1 RMC-6236-001 study, daraxonrasib demonstrated an objective response rate (ORR) of 35% for patients with tumors harboring RAS G12X mutations and 29% for those with RAS G12X, G13X, or Q61X mutations. The median progression-free survival (PFS) was 8.5 months for RAS G12X mutations and 8.1 months for G12X, G13X, or Q61X mutations. Additionally, the Phase 1 RMC-GI-102 study showed promising initial data for the combination of daraxonrasib with gemcitabine and nab-paclitaxel in the first-line setting, with an ORR of 55%. The Company believes these results support the continued development of daraxonrasib in PDAC.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement